Literature DB >> 12578438

Serum anticholinergic activity in a community-based sample of older adults: relationship with cognitive performance.

Benoit H Mulsant1, Bruce G Pollock, Margaret Kirshner, Changyu Shen, Hiroko Dodge, Mary Ganguli.   

Abstract

BACKGROUND: Serum anticholinergic activity (SAA), as measured by a radioreceptor assay, quantifies a person's overall anticholinergic burden caused by all drugs and their metabolites. In several small geriatric patient groups, SAA has been associated with cognitive impairment or frank delirium. To our knowledge, there has not yet been any systematic study of the prevalence of SAA and its effect on cognition in a community-based population.
METHODS: Serum anticholinergic activity was measured in 201 subjects who were randomly selected among the participants in an epidemiological community study, based on their age and sex. Cognitive performance was assessed with use of the Mini-Mental State Examination. The association between SAA and cognitive performance was examined using a univariate analysis and a multiple logistic regression model, adjusting for age, sex, educational level, and number of medications.
RESULTS: Serum anticholinergic activity was detectable in 180 (89.6%) participants (range, 0.50-5.70 pmol/mL). Univariate testing showed a significant association between SAA and Mini-Mental State Examination scores. Logistic regression analysis indicated that subjects with SAA at or above the sample's 90th percentile (ie, SAA >/=2.80 pmol/mL) were 13 times (odds ratio, 1.08-152.39) more likely than subjects with undetectable SAA to have a Mini-Mental State Examination score of 24 (the sample's 10th percentile) or below.
CONCLUSIONS: To our knowledge, this is the largest analysis of SAA and the first to examine its extent and relationship with cognitive performance in a community sample. Its results suggest that SAA can be detected in most older persons in the community and confirm that even low SAA is associated with cognitive impairment.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12578438     DOI: 10.1001/archpsyc.60.2.198

Source DB:  PubMed          Journal:  Arch Gen Psychiatry        ISSN: 0003-990X


  70 in total

1.  Association of anticholinergic drugs with hospitalization and mortality among older cardiovascular patients: A prospective study.

Authors:  Juho Uusvaara; Kaisu H Pitkala; Hannu Kautiainen; Reijo S Tilvis; Timo E Strandberg
Journal:  Drugs Aging       Date:  2011-02-01       Impact factor: 3.923

2.  Discontinuation of cholinesterase inhibitor treatment and determinants thereof in the Netherlands: A retrospective cohort study.

Authors:  Edeltraut Kröger; Rob van Marum; Patrick Souverein; Toine Egberts
Journal:  Drugs Aging       Date:  2010-08-01       Impact factor: 3.923

3.  The greater sensitivity of elderly APOE ε4 carriers to anticholinergic medications is independent of cerebrovascular disease risk.

Authors:  Robert D Nebes; Bruce G Pollock; Subashan Perera; Edythe M Halligan; Judith A Saxton
Journal:  Am J Geriatr Pharmacother       Date:  2012-04-24

Review 4.  Pharmacokinetics in geriatric psychiatry.

Authors:  Kristin L Bigos; Marci L Chew; Robert R Bies
Journal:  Curr Psychiatry Rep       Date:  2008-02       Impact factor: 5.285

5.  A preliminary study of anticholinergic burden and relationship to a quality of life indicator, engagement in activities, in nursing home residents with dementia.

Authors:  Ann Kolanowski; Donna M Fick; Judy Campbell; Mark Litaker; Malaz Boustani
Journal:  J Am Med Dir Assoc       Date:  2009-01-09       Impact factor: 4.669

6.  Prescription patterns of anticholinergic agents and their associated factors in Korean elderly patients with dementia.

Authors:  Eun Kyung Lee; Yu Jeung Lee
Journal:  Int J Clin Pharm       Date:  2013-05-25

7.  Neuroimaging and neurocognitive abnormalities associated with bipolar disorder in old age.

Authors:  Soham Rej; Meryl A Butters; Howard J Aizenstein; Amy Begley; Jawad Tsay; Charles F Reynolds; Benoit H Mulsant; Ariel Gildengers
Journal:  Int J Geriatr Psychiatry       Date:  2013-09-05       Impact factor: 3.485

Review 8.  Mirabegron in overactive bladder patients: efficacy review and update on drug safety.

Authors:  Katherine Warren; Helena Burden; Paul Abrams
Journal:  Ther Adv Drug Saf       Date:  2016-07-19

9.  Drug burden index score and functional decline in older people.

Authors:  Sarah N Hilmer; Donald E Mager; Eleanor M Simonsick; Shari M Ling; B Gwen Windham; Tamara B Harris; Ronald I Shorr; Douglas C Bauer; Darrell R Abernethy
Journal:  Am J Med       Date:  2009-12       Impact factor: 4.965

Review 10.  Postoperative cognitive dysfunction: Incidence and prophylaxis.

Authors:  M Coburn; A Fahlenkamp; N Zoremba; G Schaelte
Journal:  Anaesthesist       Date:  2010-02       Impact factor: 1.041

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.